Literature DB >> 33205707

Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB.

Tyler A Harm1, Shannon J Hostetter1,2, Ariel S Nenninger1, Bethann N Valentine1, N Matthew Ellinwood1, Jodi D Smith1.   

Abstract

Mucopolysaccharidosis (MPS) IIIB is a neuropathic lysosomal storage disease characterized by the deficient activity of a lysosomal enzyme obligate for the degradation of the glycosaminoglycan (GAG) heparan sulfate (HS). The pathogenesis of neurodegeneration in MPS IIIB is incompletely understood. Large animal models are attractive for pathogenesis and therapeutic studies due to their larger size, outbred genetics, longer lifespan, and naturally occurring MPS IIIB disease. However, the temporospatial development of neuropathologic changes has not been reported for canine MPS IIIB. Here we describe lesions in 8 brain regions, cervical spinal cord, and dorsal root ganglion (DRG) in a canine model of MPS IIIB that includes dogs aged from 2 to 26 months of age. Pathological changes in the brain included early microscopic vacuolation of glial cells initially observed at 2 months, and vacuolation of neurons initially observed at 10 months. Inclusions within affected cells variably stained positively with PAS and LFB stains. Quantitative immunohistochemistry demonstrated increased glial expression of GFAP and Iba1 in dogs with MPS IIIB compared to age-matched controls at all time points, suggesting neuroinflammation occurs early in disease. Loss of Purkinje cells was initially observed at 10 months and was pronounced in 18- and 26-month-old dogs with MPS IIIB. Our results support the dog as a replicative model of MPS IIIB neurologic lesions and detail the pathologic and neuroinflammatory changes in the spinal cord and DRG of MPS IIIB-affected dogs.

Entities:  

Keywords:  Sanfilippo syndrome; animal models of human disease; cerebrospinal fluid; dogs; gliosis; histology; lysosomal storage disease; mucopolysaccharidosis IIIB; neuroinflammation; physiopathology

Mesh:

Substances:

Year:  2020        PMID: 33205707      PMCID: PMC8369529          DOI: 10.1177/0300985820960128

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  60 in total

1.  Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB).

Authors:  C E Beesley; M Jackson; E P Young; A Vellodi; B G Winchester
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Evaluation of Disease Lesions in the Developing Canine MPS IIIA Brain.

Authors:  Leanne K Winner; Neil R Marshall; Robert D Jolly; Paul J Trim; Stephen K Duplock; Marten F Snel; Kim M Hemsley
Journal:  JIMD Rep       Date:  2018-06-20

3.  Neuronal ceroid lipofuscinosis in an adult American Staffordshire Terrier.

Authors:  Anna Nolte; Aimara Bello; Michaela Drögemüller; Tosso Leeb; Eva Brockhaus; Wolfgang Baumgärtner; Peter Wohlsein
Journal:  Tierarztl Prax Ausg K Kleintiere Heimtiere       Date:  2016-10-25       Impact factor: 0.596

4.  Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.

Authors:  Albert Ribera; Virginia Haurigot; Miguel Garcia; Sara Marcó; Sandra Motas; Pilar Villacampa; Luca Maggioni; Xavier León; Maria Molas; Víctor Sánchez; Sergio Muñoz; Christian Leborgne; Xavier Moll; Martí Pumarola; Federico Mingozzi; Jesús Ruberte; Sònia Añor; Fatima Bosch
Journal:  Hum Mol Genet       Date:  2014-12-18       Impact factor: 6.150

5.  Bovine mucopolysaccharidosis type IIIB.

Authors:  L Karageorgos; B Hill; M J Bawden; J J Hopwood
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

6.  Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB.

Authors:  Elizabeth Ficko-Blean; Keith A Stubbs; Oksana Nemirovsky; David J Vocadlo; Alisdair B Boraston
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

7.  Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue.

Authors:  Kimiko Hamano; Masaharu Hayashi; Kei Shioda; Ryo Fukatsu; Shuki Mizutani
Journal:  Acta Neuropathol       Date:  2007-12-04       Impact factor: 17.088

8.  Sulfamidase deficiency in a family of Dachshunds: a canine model of mucopolysaccharidosis IIIA (Sanfilippo A).

Authors:  A Fischer; K P Carmichael; J F Munnell; P Jhabvala; J N Thompson; R Matalon; P F Jezyk; P Wang; U Giger
Journal:  Pediatr Res       Date:  1998-07       Impact factor: 3.756

9.  Peripheral nervous system neuropathology and progressive sensory impairments in a mouse model of Mucopolysaccharidosis IIIB.

Authors:  Haiyan Fu; Julianne D Bartz; Robert L Stephens; Douglas M McCarty
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  A model of mucopolysaccharidosis type IIIB in pigs.

Authors:  Qiang Yang; Xueyan Zhao; Yuyun Xing; Chao Jiang; Kai Jiang; Pan Xu; Weiwei Liu; Jun Ren; Lusheng Huang
Journal:  Biol Open       Date:  2018-10-26       Impact factor: 2.422

View more
  1 in total

1.  Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.

Authors:  N Matthew Ellinwood; Bethann N Valentine; Andrew S Hess; Jackie K Jens; Elizabeth M Snella; Maryam Jamil; Shannon J Hostetter; Nicholas D Jeffery; Jodi D Smith; Suzanne T Millman; Rebecca L Parsons; Mark T Butt; Sundeep Chandra; Martin T Egeland; Ana B Assis; Hemanth R Nelvagal; Jonathan D Cooper; Igor Nestrasil; Bryon A Mueller; Rene Labounek; Amy Paulson; Heather Prill; Xiao Ying Liu; Huiyu Zhou; Roger Lawrence; Brett E Crawford; Anita Grover; Ganesh Cherala; Andrew C Melton; Anu Cherukuri; Brian R Vuillemenot; Jill C M Wait; Charles A O'Neill; Jason Pinkstaff; Joseph Kovalchin; Eric Zanelli; Emma McCullagh
Journal:  J Pharmacol Exp Ther       Date:  2022-06-18       Impact factor: 4.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.